<DOC>
	<DOCNO>NCT01354587</DOCNO>
	<brief_summary>The purpose study measure change Treatment Satisfaction Questionnaire Medication area effectiveness , side effect , convenience administration medication Primary Immunodeficiency Disorder ( PIDD ) subject transition subcutaneous Vivaglobin® Hizentra® .</brief_summary>
	<brief_title>Evaluation Efficacy Tolerability Hizentra®</brief_title>
	<detailed_description>This trial evaluate subject Primary Immunodeficiency Disorder ( PIDD ) currently self-infusing Vivaglobin therapy least six month prior change Hizentra® therapy . Following screen enrollment , subject continue self-infuse Vivaglobin® seven infusion convert subcutaneous Hizentra® treatment continue next 6 month . The study determine Hizentra® provide improved subject satisfaction Treatment Satisfaction Questionnaire Medication . Diaries relate local site reaction , number infusion sit per subject/per dose , volume Hizentra® per site , duration infusion , systemic side effect new medication dose IgG level antibody titer , local site reaction Hizentra® .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Subjects currently selfinfusing Vivaglobin® least six month prior enrollment . Diagnosis antibody deficiency due primary immune deficiency disease . Stable serum IgG level &gt; 550 mg/dl Vivaglobin® base two determination least 8 week apart obtain within 6 month entry . Willing sign consent follow study schedule . 1 year 75 year age . Evidence acute systemic illness infection within four week screen enrollment . Any serious grade 3 great toxicity screening . History bleed chronic skin disorder . Selective IgA deficiency absence antibody deficiencies History anaphylactic severe systemic reaction Vivaglobin . Pregnant breastfeeding female . Use systemic premedication prior SCIG . Protein lose enteropathy nephritic syndrome . Any condition opinion investigator would interfere conduct study . Subject guardian unwilling sign consent adhere study schedule .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>immunodeficiency</keyword>
</DOC>